[Fludarabine in the treatment of chronic lymphocytic leukemia and other lymphoproliferative disorders].
Fludarabine, an analogue of arabinosyl adenine, used since 1986 proved to be a new agent effective particularly in chronic lymphocytic leukaemia. About 35% of patients refractory to previous cytostatic treatment and about 75% of untreated patients obtained complete remissions. Nearly 90% of them revealed no minimal residual disease and no relapse during 2 years of observation. Worse response was found in patients with other low grade non-Hodgkin's lymphomas.
Pawelski
S
S
Instytutu Hematologii i Transfuzjologii w Warszawie.
D000970:Antineoplastic Agents / Q000627:therapeutic use*; D006801:Humans; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000188:drug therapy*; D008228:Lymphoma, Non-Hodgkin / Q000188:drug therapy; D008232:Lymphoproliferative Disorders / Q000188:drug therapy*; D012074:Remission Induction; D014740:Vidarabine / Q000031:analogs & derivatives* / Q000627:therapeutic use
D000970:Antineoplastic Agents; D014740:Vidarabine; C024352:fludarabine
Fludarabina w leczeniu przewlekłej białaczki limfatycznej i innych zespołów limfoproliferacyjnych.